← Back

News

Thursday, 24 March 2016

Cerium oxide nanoparticles may be of therapeutic value in chronic liver disease

Researchers from clinical and basic research institutes located in Barcelona used Cerium oxide NPs to treat cirrhosis in model rats. In a work published in Journal of Hepatology, they observed how it has dramatic beneficial effects in reducing inflammation and allowing tissue reparation. What makes nanoceria very appealing is its high capacity to buffer electrons from an oxidant/reducing environment, followed by the capture or release of oxygen, or molecular oxygen species which are very reactive oxygen species (ROS).

 

Researchers from clinical and basic research institutes located in Barcelona used Cerium oxide NPs to treat cirrhosis in model rats. In a work published in Journal of Hepatology, they observed how it has dramatic beneficial effects in reducing inflammation and allowing tissue reparation. What makes nanoceria very appealing is its high capacity to buffer electrons from an oxidant/reducing environment, followed by the capture or release of oxygen, or molecular oxygen species which are very reactive oxygen species (ROS).

Cerium oxide NPs have proven to behave as free radical scavenger and anti-inflammatory agents. The last authors of the work are Dr. Wladimiro Jiménez, Head of the Hospital Clínic of Barcelona’s Department of Biochemistry and Molecular Genetics, and the ICREA Research Prof Victor Puntes, Group Leader at the Institut Català de Nanociència i Nanotecnologia (ICN2) and the Vall d'Hebron Insitute of Research (VHIR).

The NPs used in this work were been designed to maximize catalytic activity (and decrease dose) and at the same time to localize in the inflamed area of the liver. This is done controlling interactions with proteins and tuning morphology (size and shape) of the NP to then control in-liver extravasation and in-inflammation accumulation. Once the inflamed area is reached, the NPs start decreasing the local excess of ROS until it reaches healthy tissue levels and the whole inflammation decreases.

Arterial pressure and portal pressure, among other, were assessed and serum samples obtained to measure standard hepatic and renal function tests. The researchers observed in animal models that Cerium oxide NPs protect against chronic liver injury attenuating the intensity of the inflammatory response. These encouraging results are the basis of the flowering long term collaboration among the research groups from IDIBAPS – Hospital Clínic and ICN2 – Vall d’Hebron. The liver is a complex and fundamental organ and NPs such as Cerium oxide NPs may have useful effects in monitoring and treatment of the liver diseases.

 

Publication Reference:

Oró D, Yudina T, Fernández-Varo G, Casals E, Reichenbach V, Casals G, González de la Presa B, Sandalinas S, Carvajal S, Puntes V, Jiménez W. Cerium oxide nanoparticles reduce steatosis, portal hypertension and display anti-inflammatory properties in rats with liver fibrosis. J Hepatol. 2016 Mar

http://www.ncbi.nlm.nih.gov/pubmed/26519601

 

Information via: www.atlasofscience.org